Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors
Changxia Shao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wei Zhou(Broad Institute), Elisha J. Dettman(Eutropics Pharmaceuticals (United States)), Yixin Ren(Merck & Co., Inc., Rahway, NJ, USA (United States)), Liam C. Lee(Center for Cancer Research), Fan Jin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Heng Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cai Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alexander Gozman(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 3
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Rapidly in Situ Forming Biodegradable Robust Hydrogels by Combining Stereocomplexation and Photopolymerization
|Journal of the American Chemical Society|2007|156
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
|Journal of Thoracic Oncology|2016|156